PCL 膠原蛋白增生劑誘發的白斑症

摘 要：

膠原蛋白刺激劑常用作皮膚填充劑，以在美容實踐中治療老化和體積流失。注射部位反應如水腫和紅腫在接受注射後並不罕見。基於聚己內酯（PCL）的填充劑Ellansé（Sinclair Pharmaceuticals）是一種膠原蛋白刺激劑，具有經證實的安全性。然而，由於宿主免疫因素，可能會出現結節和肉芽腫等併發症。白斑症是一種慢性脫色素疾病，難以治療，且可能是不可逆的。據我們所知，文獻中尚未報導與可注射膠原蛋白刺激劑相關的白斑症病例。在此，我們報告了首例23歲女性在接受基於PCL的膠原蛋白刺激劑填充劑後出現白斑症的病例。 在這篇報告中，我們詳細描述了患者的臨床表現、診斷過程及治療方案，並探討了可能的病理機制及該類併發症的潛在風險。希望這一病例報告能夠引起臨床醫生的注意，並促進對該類併發症的認識和研究。

Introduction Injectable collagen stimulators are commonly used as dermal fillers to treat aging and volume loss in aesthetic practices. Injection site reactions, such as edema and redness, are not uncommon after receiving injectables.1 The polycaprolactone (PCL)-based filler Ellansé (Sinclair Pharmaceuticals) is a collagen stimulator with a proven safety profile. However, complications, such as nodularity and granulomas due to the host’s immune factors, can occur. Vitiligo is a chronic depigmentation disorder that is difficult to treat and may be irreversible. To our knowledge, vitiligo associated with injectable collagen stimulators has not been reported previously in the literature. Herein, we report the first case of a 23-year-old woman with vitiligo after receiving a PCL-based collagen stimulator filler.